WORX vs VEEV vs DOCS vs CRM vs HCAT

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus -3. 7% for SCWorx Corp. (WORX). Salesforce, Inc. (CRM) offers the better valuation at 23. 3x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Veeva Systems Inc. (VEEV) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Salesforce, Inc.

(CRM) is the cheapest at 23. 3x versus Veeva Systems Inc. at 30. 6x. On forward P/E, Health Catalyst, Inc. is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus Salesforce, Inc. 's 1. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Salesforce, Inc.

(CRM) delivered a total return of -13. 3%, compared to -99. 8% for SCWorx Corp. (WORX). Over 10 years, the gap is even starker: VEEV returned +512. 1% versus WORX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 72β versus Health Catalyst, Inc. 's 1. 93β — meaning HCAT is approximately 166% more volatile than VEEV relative to the S&P 500. On balance sheet safety, SCWorx Corp. (WORX) carries a lower debt/equity ratio of 0% versus 11% for Salesforce, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus -3. 7% for SCWorx Corp. (WORX). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -154. 4% for SCWorx Corp. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus Salesforce, Inc. 's 1. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Health Catalyst, Inc. (HCAT) trades at 13. 5x forward P/E versus 18. 8x for Veeva Systems Inc. — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 68. 5% to $280. 10.

In this comparison, CRM (0.

9% yield) pays a dividend. WORX, VEEV, DOCS, HCAT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Salesforce, Inc.

(CRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75), 0. 9% yield, +148. 6% 10Y return). Health Catalyst, Inc. (HCAT) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRM: +148. 6%, HCAT: -96. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WORX (Healthcare) and VEEV (Healthcare) and DOCS (Healthcare) and CRM (Technology) and HCAT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WORX is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; DOCS is a small-cap high-growth stock; CRM is a mid-cap quality compounder stock; HCAT is a small-cap quality compounder stock. CRM pays a dividend while WORX, VEEV, DOCS, HCAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.